Clinical Trial Update: Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial comparing a neoantigen DNA vaccine alone versus combined with durvalumab in triple-negative breast cancer after standard-of-care therapy; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Neoantigen DNA Vaccine

Snippet

Sponsor: Washington University School of Medicine | Conditions: Triple Negative Breast Cancer, Triple Negative Breast Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2023-12-14